Enzo Biochem Inc

Enzo Biochem — Proxy Contest (January 2020)

61 slides from Enzo Biochem's proxy contest presentation, Jan 17, 2020

  1. Slide 1: Investor Presentation January 2020

    Investor Presentation January 2020

  2. Slide 2: Disclaimer

    Disclaimer The views expressed in this presentation (this ” Presentation “) represent the opinion of Enzo Biochem, Inc. (the ” Company “). This Presentation is for informational purposes only, and it does not have regard to the specific investment objective, financial situations, suitability or part

  3. Slide 3: Situation Overview

    Situation Overview • Harbert Discovery Fund (“Harbert”) — a short - term oriented activist hedge fund focused on micro - cap companies that we believe has no operational experience or background in our sector — is seeking to replace two highly qualified directors up for election at Enzo’s 2019 Annua

  4. Slide 4: Situation Overview (cont'd)

    Situation Overview (cont’d) • Enzo’s strategy is the product of extensive analysis and thoughtful planning and is showing meaningful progress – Our business plan is well - vetted and deliberate; in contrast, we believe Harbert’s ill - conceived arguments demonstrate an utter lack of understanding of

  5. Slide 5: Enzo investment case summary

    x Innovator, disruptor and groundbreaking pioneer in modern biological research x Thoughtful and well - considered transition to a fully integrated healthcare company x Business model and operational structure thoughtfully designed to capitalize on industry headwinds and offer unique value propositi

  6. Slide 6: Enzo's Market Opportunity Is Substantial

    Enzo’s Market Opportunity Is Substantial 6 By continuing to execute its three - pronged strategy for value creation, Enzo is poised to capitalize on significant market opportunity Harbert threatens to jeopardize Enzo’s strategy at exactly the wrong time Diagnostic Assay North America Global Infectio

  7. Slide 7: Executing Three-Pronged Strategy for Value Creation

    “We continue to believe that Enzo’s strategy to be a low cost provider of diagnostic products and services — ’ central capability’ for smaller labs — should resonate, and it appears Enzo is progressing towards having a critical mass on the product side to engage in a fuller rollout of the strategy”

  8. Slide 8: Neither Harbert Nor Its Nominees Has Relevant Experience or a Plan for Enzo

    Neither Harbert Nor Its Nominees Has Relevant Experience or a Plan for Enzo Harbert refused to engage in constructive discussions with Enzo, including initially refusing to provide the identities of their nominees; Harbert’s nominees have declined to participate in a standard nominee interview proce

  9. Slide 9: Unqualified and Inferior Nominees; What Is Harbert Hiding?

    Unqualified and Inferior Nominees Lack of Healthcare Experience What Is Harbert Hiding? We believe Harbert’s disingenuous behavior and lack of healthcare experience raise alarming questions about their intentions Refusal to Participate in Board Refreshment Process 1 2 3 9 Harbert’s lack of cooperati

  10. Slide 10: The Choice for Shareholders Is Clear: Vote WHITE Card

    The Choice for Shareholders Is Clear: Vote for Enzo’s Nominees on the WHITE Card 10

  11. Slide 11: Table of Contents

    Table of Contents Enzo’s Business, Strategy and Progress Our Qualified, Engaged Board of Directors Harbert and Its Nominees Lack Relevant Experience Harbert’s Unfounded Critiques of Enzo Our Recommendation to Shareholders 11 12 31 38 45 56 Page

  12. Slide 12: Enzo's Business, Strategy and Progress

    Our Recommendation to Shareholders Enzo’s Business, Strategy and Progress Our Qualified, Engaged Board of Directors Harbert and Its Nominees Lack Relevant Experience Harbert’s Unfounded Critiques of Enzo 12

  13. Slide 13: Snapshot of Enzo

    Snapshot of Enzo 13 Enzo’s unique, vertically integrated and self - funded novel diagnostics model has resulted in a track record of innovation Self - Funded R&D Robust Licensing Program Generating $154m in Income since 2011 2 $1.3bn 3 in Revenue Derived from IP Commercialization to Date $ 81m in FY

  14. Slide 14: Overview of Enzo's business highlights

    • Enzo is the new model for a modern diagnostics company, with a unique and synergistic vertical integration model that fuels Enzo’s value creation - Enzo’s diagnostics, clinical services and innovation and IP technology platforms are interdependent and allow Enzo to deliver 30 – 50% 1 cost savings

  15. Slide 15: Enzo's Unique Novel Diagnostics Model Is Comprehensive and Delivers Savings

    Enzo’s Unique Novel Diagnostics Model Is Comprehensive and Delivers Savings 15 Clinical Results Analytical Detection Sample Processing Sample Collection Patient Sample Diagnostics Workflow Diagnostics Segments Enzo’s open system platform delivers solutions that align with diagnostics workflow and en

  16. Slide 16: Enzo's Vertical Integration Strength

    Enzo’s Vertical Integration Strength Under the leadership of an engaged management team and Board, Enzo has developed into a uniquely integrated novel diagnostics company Unique vertical integration is the product of extensive strategic planning and enables innovation/disruption, cost savings and op

  17. Slide 17: Enzo's Three Interdependent Businesses

    Enzo’s Three Interdependent Businesses 17 • Develops, formats and manufactures high - performance diagnostics products on a large scale and markets the products on a global basis Diagnostics • Internal validation enables Enzo to forego higher cost of licensing an outside CRO (which may have other pr

  18. Slide 18: Typical Diagnostics Company Timeline vs Enzo

    Typical Diagnostics Company Timeline While Enzo’s Novel Diagnostics Structure and Resources Are Complete and Integrated … Enzo’s novel diagnostics model positions the company to manage costs while investing in technological innovation and create a platform that is fully automated, high capacity, low

  19. Slide 19: Rest of the Molecular Diagnostics Market Remains Incomplete and Fragmented

    …the Rest of the Molecular Diagnostics Market Remains Incomplete and Fragmented Biotech x Molecular Diagnostics Products Through licensing $$ Clinical Services Services Through licensing $$ x x x x x x x x Concept to Commercialization Other market participants have been unable to vertically integrat

  20. Slide 20: Enzo Is Well-Positioned to Succeed Despite Recent Industry Headwinds

    Enzo is Well - Positioned to Succeed Despite Recent Industry Headwinds In the past five years, Enzo has laid the foundation for a pioneering model for a novel diagnostics business that effectively responds to cost pressures faced by clinical labs 20 • Industry dynamics impose severe, increasing pres

  21. Slide 21: Enzo's Cost Savings Proposition Creates a Unique Market Opportunity

    Enzo’s Cost Savings Proposition Creates a Unique Market Opportunity 21 Enzo’s Unique Low - Cost Strategy Allows Favorable Positioning Relative to Competitors 1 Company reports . “It was tough pre - 2018 and with the PAMA pricing pressure, it’s become even tougher . Frankly, I’m amazed that so many i

  22. Slide 22: Enzo's Unique Value Proposition to Customers

    Enzo’s Unique Value Proposition to Customers Potential Savings: • Cumulative royalty relief — Enzo owns ALL IPs – IP generation process is already paid for • Low cost of goods – Enzo’s cumulative technology capability is the foundation – Enzo’s robust product development pipeline creates platforms w

  23. Slide 23: Why Haven't Other Players Addressed the Problem?

    Why Haven’t Other Players Addressed the Problem? Others in the industry have not been able to adapt to today’s reimbursement pressures, creating opportunity for Enzo to disrupt the antiquated single - platform - centric model • Clinical labs have made substantial efforts to reduce costs and focus on

  24. Slide 24: Executing Three-Pronged Strategy for Value Creation Progress

    Executing Three - Pronged Strategy for Value Creation Progress Form Strategic Relationships for Diagnostic Growth Actively engaging with several global life sciences, healthcare and medical device companies Seeking to form strategic relationships or new venture creation across key product platforms

  25. Slide 25: Recent Strategic Highlights

    Recent Strategic Highlights 25 3 ~50% Expansion in Personnel Supporting Commercialization x Project Managers Product Managers Customer Support Application Scientists Switzerland Belgium France England Michigan New York Selected Commercial Offices Expanding Good Manufacturing Practices Facilities x x

  26. Slide 26: Enzo's Product and Development Wins in 2019

    Enzo’s Product and Development Wins in 2019 26 2019 Highlights and Announcements » Entered into a settlement agreement with Roche Diagnostics and Roche Molecular Systems » Entered into a state licensing agreement with Hologic and Grifols Diagnostic Solutions to settle all outstanding patent disputes

  27. Slide 27: Enzo's Market Opportunity Is Substantial

    Enzo’s Market Opportunity Is Substantial 27 By continuing to execute its three - pronged strategy for value creation, Enzo is poised to capitalize on significant market opportunity Harbert threatens to jeopardize Enzo’s strategy at exactly the wrong time Diagnostic Assay North America Global Infecti

  28. Slide 28: Enzo Has a Legacy of Groundbreaking Innovation

    Enzo Has a Legacy of Groundbreaking Innovation Enzo’s track record of industry disruption and strategic reinvention positions us for success 28 1976 1981 1982 1982 1983 1984 1984 1986 2004 2005 2007 2008 2009 2015 2015 2016 2017 2018 2019 Enzo is incorporated Breakthrough technology for non - radioa

  29. Slide 29: Self-Funded R&D and a Profitable Licensing Strategy

    Continued Commitment to Self - Funded R&D and a Profitable Licensing Strategy Enzo has an extensive IP portfolio, which has meaningfully expanded over the past decade 107 107 145 149 245 314 336 343 406 Enzo’s Patent Portfolio (# of Patents) While larger competitors continue to infringe on Enzo’s IP

  30. Slide 30: Enzo's Strong, Experienced Management Team

    Enzo’s Strong, Experienced Management Team Dr. Elazar Rabbani Co - Founder, CEO & Chairman Barry Weiner Co - Founder, President & Executive Director x Co - founder of Enzo Biochem x Extensive, relevant experience in molecular biology x Inventor of multiple, pioneering Enzo 400+ patents x Published 4

  31. Slide 31: Our Qualified, Engaged Board of Directors

    Our Recommendation to Shareholders Enzo’s Business, Strategy and Progress Our Qualified, Engaged Board of Directors Harbert and Its Nominees Lack Relevant Experience Harbert’s Unfounded Critiques of Enzo 31

  32. Slide 32: Overview of Enzo's Board of Directors

    Appointed as of December 31, 2019 Resigned as of December 31, 2019 Our current Board provides effective oversight and is best suited to drive Enzo’s strategy Overview of Enzo’s Board of Directors 32 Elazar Rabbani Co - Founder, Chairman and CEO Lead Inventor and Named Patent Holder in 400+ Patents |

  33. Slide 33: Barry Weiner

    Barry Weiner Barry Weiner Co - Founder & President x President and Director and a co - founder of Enzo Biochem x Committed to Enzo: has served as the Company’s President since 1996 and previously held the position of Chief Financial Officer and Executive Vice President x Operational, strategic and f

  34. Slide 34: Dr. Bruce Hanna, Ph.D.

    Dr. Bruce Hanna, Ph.D. Dr. Bruce Hanna Director x Director since January 2017 (3 - year tenure; most recently added Director until Rebecca Fischer’s appointment) x Clinical Professor of Pathology and Clinical Professor of Microbiology at the New York University School of Medicine, Adjunct Professor

  35. Slide 35: Recently Announced Board Refreshment

    Recently Announced Board Refreshment On December 31, 2019, following a robust, proactive search process, Enzo added Rebecca Fischer to the Board 35 Rebecca Fischer Director x Chief Financial Officer at New York Health & Hospitals/Bellevue Hospital Center in New York City x Addition followed a delibe

  36. Slide 36: Board Values Feedback from Multi-Year Engagement Program

    Board Values Feedback Received from Multi - Year Engagement Program on Board, Governance and Compensation Matters Feedback integrated into Board’s decision - making process 36 Engagements and Improvements » 55% Say - on - Pay result led to initiation of a robust shareholder engagement process » Enzo

  37. Slide 37: Appointment of Ms. Fischer Is Result of Robust Search Process

    37 Board meeting where refreshment process was discussed Appointment of Ms. Fischer Is the Result of a Robust, Proactive Search Process Jan. 2019 Feb. Mar. Apr. May Jun. Jul. Aug. Sep. Oct. Nov. Dec. Rebecca Fischer appointed to the Enzo Board and put up for election at 2020 AGM Rebecca Fischer’s ap

  38. Slide 38: Harbert and Its Nominees Lack Relevant Experience

    Our Recommendation to Shareholders Enzo’s Business, Strategy and Progress Our Qualified, Engaged Board of Directors Harbert and Its Nominees Lack Relevant Experience Harbert’s Unfounded Critiques of Enzo 38

  39. Slide 39: Unqualified and Inferior Nominees; What Is Harbert Hiding?

    Unqualified and Inferior Nominees Lack of Healthcare Experience What Is Harbert Hiding? We believe Harbert’s disingenuous behavior and lack of healthcare experience raise alarming questions about their intentions Refusal to Participate in Board Refreshment Process 1 2 3 39 Harbert’s lack of cooperat

  40. Slide 40: Harbert's Inexperience in Healthcare Is Troubling

    Harbert’s Inexperience in Healthcare Is Troubling [CELLRANGE] [CELLRANGE] [CELLRANGE] [CELLRANGE] [CELLRANGE] [CELLRANGE] [CELLRANGE] [CELLRANGE] [CELLRANGE] [CELLRANGE] [CELLRANGE] [CELLRANGE] [CELLRANGE] Q1 2016 Q2 2016 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 Q4 2017 Q1 2018 Q2 2018 Q3 2018 Q4 201

  41. Slide 41: Harbert's Problematic History in New York

    Harbert’s Problematic History in New York “The New York attorney general’s office on Tuesday said it reached a $ 40 million settlement with an Alabama investment firm over the failure of members of an investment management company it sponsored to pay millions in New York state taxes [ … ]” “Our inve

  42. Slide 42: Harbert's Nominees Do Not Offer Value for Enzo

    Harbert’s Nominees Do N ot Offer V alue for Enzo Because Harbert’s nominees declined to participate in any interview process, we have no basis for evaluating them except based on their resumes Harbert’s nominees’ resumes show they are not the right Directors for Enzo Fabian Blank Peter Clemens, IV U

  43. Slide 43: Harbert Nominee: Fabian Blank

    Harbert Nominee: Fabian Blank Employment history is hyper - regional and non - U.S. (Georgia (former Soviet Republic), Israel and Germany), of questionable value to Enzo and complicates Board participation According to his resume, he has at least 7 current affiliations — how can he devote the time r

  44. Slide 44: Harbert Nominee: Peter Clemens, IV

    Harbert Nominee : Peter Clemens, IV Peter Clemens, IV Has not served on any public company Boards Experience disclosed in resume (our sole basis for evaluating him) is not relevant to Enzo Named defendant in litigation alleging that, while at Caremark, he received backdated stock options and then ac

  45. Slide 45: Harbert's Unfounded Critiques of Enzo

    Our Recommendation to Shareholders Enzo’s Business, Strategy and Progress Our Qualified, Engaged Board of Directors Harbert and Its Nominees Lack Relevant Experience Harbert’s Unfounded Critiques of Enzo 45

  46. Slide 46: "Harbert doesn't know anything about the laboratory business"

    “Harbert doesn’t know anything about the laboratory business” – Kenan Lucas, Harbert Portfolio Manager, 5/7/2019 46

  47. Slide 47: Harbert Claim vs Reality

    Harbert Claim Reality Enzo should conduct a “full exploration of strategic alternatives, with a focus on potential sales of non - core assets and intellectual property” x • Enzo has announced an exploration of strategic alternatives for its Therapeutics business • The remaining Labs, Diagnostic and

  48. Slide 48: Claim: Enzo should conduct a full exploration of strategic alternatives

    Harbert Claim: Enzo should c onduct a full e xploration of strategic a lternatives Reality: Enzo is already committed to active portfolio management and a break - up of the business would entail meaningful dis - synergies A x Now is not the right time to separate Enzo’s remaining businesses given re

  49. Slide 49: Claim: Enzo has not delivered on AmpiProbe or partnerships

    Harbert Claim: Enzo has n ot delivered on AmpiProbe technology potential or strategic partnerships Reality: Enzo is actively engaged in discussions with potential partners and has meaningfully expanded AmpiProbe technology’s scalability and applications x Developed AmpiProbe technology to increase s

  50. Slide 50: Claim: Enzo lacks scale for labs-to-labs model

    Harbert Claim: Enzo lacks the scale/expertise for the ” labs - to - labs ” business model to succeed Reality : Enzo has made progress and is well - positioned to execute on the ” labs - to - labs ” strategy, recently capitalizing on multiple commercial opportunities for its Labs business C x Formali

  51. Slide 51: Claim: Enzo's IP has not produced returns

    Harbert Claim: Enzo’s IP has not produced returns Reality : Enzo has generated over $1.3bn 1 in revenue derived from IP commercialization to date Enzo’s legal settlements far outweigh legal costs by a factor of more than 3x $4 $4 $6 $7 $9 $6 $2 $5 $3 $7 $30 $5 $8 $14 $59 $1 $1 $29 Total Legal Expend

  52. Slide 52: Claim: Enzo's compensation is excessive

    Harbert Claim: Enzo’s compensation is excessive, misaligned and unjustifiable Reality: CEO compensation is lowest among peer group Enzo’s 3 - Year Average CEO Compensation Compared to Proxy Peers ($m) A comparison of Enzo’s CEO compensation relative to peers reveals it is entirely appropriate 52 E H

  53. Slide 53: Components of Compensation

    1 In 2018, other NEOs included Barry W. Weiner, James M. O’Brien, Dieter Schapfel, Kara Cannon and Bruce A. Dey. Components of Compensation 2019 Compensation Recent Enhancements Component Metrics Base Salary (Cash) Reviewed annually Non - Equity Incentive Compensation (At - Risk Cash) 30% – 60% Fina

  54. Slide 54: Governance framework responsive to shareholder feedback

    Enzo’s governance framework is appropriately tailored to its specific situation and highly responsive to shareholder feedback; nonetheless, the framework remains in - line with peers and industry benchmark Majority Voting Proposal x In response to shareholder feedback received via Enzo’s proactive e

  55. Slide 55: Claim: Harbert's nominees are highly qualified candidates

    Harbert’s Claim: Harbert’s nominees are highly q ualified c andidates Reality: Harbert’s candidates h ave n o d irect r elevant e xperience for Enzo Fabian Blank Peter Clemens, IV Employment history is hyper - regional and non - U.S. (Georgia (former Soviet Republic), Israel and Germany), of questio

  56. Slide 56: Our Recommendation to Shareholders

    Our Recommendation to Shareholders Enzo’s Business, Strategy and Progress Our Qualified, Engaged Board of Directors Harbert and Its Nominees Lack Relevant Experience Harbert’s Unfounded Critiques of Enzo 56

  57. Slide 57: Enzo investment case summary

    x Innovator, disruptor and groundbreaking pioneer in modern biological research x Thoughtful and well - considered transition to a fully integrated healthcare company x Business model and operational structure thoughtfully designed to capitalize on industry headwinds and offer unique value propositi

  58. Slide 58: Neither Harbert Nor Its Nominees Has Relevant Experience or a Plan for Enzo

    Neither Harbert Nor Its Nominees Has Relevant Experience or a Plan for Enzo Harbert refused to engage in constructive discussions with Enzo, including initially refusing to provide the identities of their nominees; Harbert’s nominees have declined to participate in a standard nominee interview proce

  59. Slide 59: Enzo's Nominees Are the Clear Choice

    Enzo’s Nominees Are the Clear Choice Barry Weiner Dr. Bruce Hanna x Demonstrated ability to execute strategy, develop unmatched innovation and fund the Company’s growth without dilution of shareholders x Contribute extensive, relevant medical experience x Integrally involved in the development of En

  60. Slide 60: The Choice for Shareholders Is Clear: Vote WHITE Card

    The Choice for Shareholders Is Clear: Vote for Enzo’s Nominees on the WHITE Card 60

  61. Slide 61: Questions? Need Help Voting?

    Questions? Need Help Voting? Please contact our Strategic Shareholder Advisor and Proxy Solicitation Agent, Kingsdale Advisors CONTACT US: Kingsdale Advisors 1 - 888 - 518 - 1554 (toll - free in North America) 416 - 867 - 2272 (outside of North America) email: [email protected] This image ca

Enzo Biochem — Proxy Contest (January 2020) on 6ix